US Patent

US10646550 — Use of C-type natriuretic peptide variants to treat skeletal dysplasia

Method of Use · Assigned to Biomarin Pharmaceutical Inc · Expires 2036-08-01 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of C-type natriuretic peptide variants to treat skeletal dysplasias and related disorders.

USPTO Abstract

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3927 — vosoritide
U-3927 — vosoritide
U-3927 — vosoritide

Patent Metadata

Patent number
US10646550
Jurisdiction
US
Classification
Method of Use
Expires
2036-08-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.